LENZ Therapeutics, Inc.: directors' dealings · United States · SEC (Form 4)

About LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc. is a United States-based biopharmaceutical company listed on NASDAQ under the ticker LENZ. Headquartered operationally in Solana Beach, California, the company is focused on ophthalmology, with a particular emphasis on presbyopia, a large age-related vision condition that affects near sight. LENZ was founded in 2013 under the name Presbyopia Therapies, Inc., and later changed its corporate name to LENZ Therapeutics in June 2021. Its corporate history shows a clear progression from an early-stage development biotech to a commercial-stage company anchored by a recently approved product. The company’s strategic center is VIZZ (aceclidine ophthalmic solution) 1.44%, which LENZ describes as the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia. That positioning is important: presbyopia is widespread, but the treatment landscape has historically been limited, making the market attractive for differentiated ophthalmic therapies. Prior to approval, LENZ advanced VIZZ through registration-enabling Phase 3 clinical work and submitted a New Drug Application to the FDA in 2024. The FDA approved VIZZ on July 31, 2025, and LENZ launched the product commercially in the United States in August 2025. For investors, this was the key inflection point that transformed the company from a development story into a commercial execution story. From a competitive standpoint, LENZ occupies a specialized niche with meaningful upside potential. Its value proposition rests on a once-daily eye-drop format, a focused presbyopia indication, and a first-mover advantage in aceclidine-based therapy. At the same time, the company still has many of the characteristics of an emerging commercial biotech: concentration in a single lead product, the need to scale awareness and adoption, and execution risk around commercialization, physician uptake, and market penetration. Until recently, LENZ had no approved product revenue, so the company’s financial profile remains in transition. Geographically, the business is currently concentrated in the United States, which is also its initial commercial market. However, LENZ has started to broaden its geographic optionality. In March 2026, the company announced submission of a marketing authorization application to the European Medicines Agency for VIZZ, indicating an early step toward international expansion. That matters for long-term investors because the presbyopia opportunity is not limited to the U.S., and LENZ is beginning to build a global regulatory pathway. For French-speaking investors, LENZ should be viewed as a health and pharma name on NASDAQ in the United States, with a recent regulatory win, a commercial launch underway, and an international expansion strategy in development. The core question now is not scientific validation, but commercial execution and the pace at which VIZZ can establish itself in a highly specialized ophthalmology market.